Alnylam Pharmaceuticals (ALNY) Receives News Sentiment Score of 0.18
News headlines about Alnylam Pharmaceuticals (NASDAQ:ALNY) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.3305109601585 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Alnylam to Webcast Presentation at BMO Capital Markets Prescriptions for Success Healthcare Conference (finance.yahoo.com)
- Why Alnylam Pharmaceuticals Rose 12.7% in November – Motley Fool (fool.com)
- Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : December 7, 2017 (finance.yahoo.com)
- PCSK9 Inhibitors and Cardiovascular Outcomes Trials: Everything You Need to Know (medscape.org)
ALNY has been the topic of several analyst reports. Barclays lifted their target price on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, August 10th. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an “equal weight” rating in a research note on Thursday, August 10th. Chardan Capital reiterated a “buy” rating and issued a $124.00 target price (down previously from $131.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $56.00 target price (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. Finally, Credit Suisse Group reiterated a “buy” rating and issued a $96.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 11th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $121.85.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $2.16 during midday trading on Friday, reaching $130.89. The company had a trading volume of 745,058 shares, compared to its average volume of 1,145,674. Alnylam Pharmaceuticals has a 52-week low of $35.98 and a 52-week high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. Alnylam Pharmaceuticals’s quarterly revenue was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.21) EPS. sell-side analysts predict that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current fiscal year.
In other news, SVP Laurie Keating sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the transaction, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at approximately $5,639,435. The sale was disclosed in a filing with the SEC, which is available at this link. Also, President Barry E. Greene sold 76,815 shares of the company’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at $16,539,900. The disclosure for this sale can be found here. Insiders sold 393,212 shares of company stock valued at $48,109,436 over the last three months. 4.30% of the stock is currently owned by corporate insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.